scholarly article | Q13442814 |
P50 | author | Ernst J. Schaefer | Q124678742 |
P2093 | author name string | Lisa Cook | |
Margaret R Diffenderfer | |||
Danyal Ibrahim | |||
Steven B Kleiboeker | |||
Dorothy B Wakefield | |||
Syed A Hussain | |||
Rebecca Crowell | |||
Kendra Williams | |||
Jessica McKenzie | |||
Latha Dulipsingh | |||
Jennifer Puff | |||
Patricia Nabors | |||
Colleen Lima | |||
Mary Onoroski | |||
Reginald J Eadie | |||
P2860 | cites work | The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis | Q27001157 |
Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. | Q30398715 | ||
Use of convalescent plasma therapy in SARS patients in Hong Kong | Q47875099 | ||
Treatment of severe acute respiratory syndrome with convalescent plasma. | Q51660103 | ||
Treatment with convalescent plasma for influenza A (H5N1) infection | Q81391936 | ||
Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2 | Q87726414 | ||
Virological assessment of hospitalized patients with COVID-2019 | Q89379643 | ||
The convalescent sera option for containing COVID-19 | Q90296531 | ||
Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study | Q90658465 | ||
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma | Q90702138 | ||
Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV | Q90713511 | ||
Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Infected Patients | Q90714901 | ||
Clinical and virological data of the first cases of COVID-19 in Europe: a case series | Q90732490 | ||
Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how | Q91510657 | ||
Treatment With Convalescent Plasma for Critically Ill Patients With SARS-CoV-2 Infection | Q91537559 | ||
Effectiveness of convalescent plasma therapy in severe COVID-19 patients | Q91611037 | ||
Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019 | Q91660911 | ||
Detection of serum IgM and IgG for COVID-19 diagnosis | Q91748689 | ||
Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea | Q91849623 | ||
Treatment with convalescent plasma for COVID-19 patients in Wuhan, China | Q91952878 | ||
Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients | Q92013616 | ||
Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study | Q92128365 | ||
Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19 | Q93150027 | ||
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections | Q96577059 | ||
Characteristics and serological patterns of COVID-19 convalescent plasma donors: optimal donors and timing of donation | Q97079201 | ||
Potential effective treatment for COVID-19: systematic review and meta-analysis of the severe infectious disease with convalescent plasma therapy | Q97438796 | ||
The Emerging Role of Convalescent Plasma in the Treatment of COVID-19 | Q97545650 | ||
Associations between blood type and COVID-19 infection, intubation, and death | Q102058933 | ||
P921 | main subject | virology | Q7215 |
SARS-CoV-2 | Q82069695 | ||
convalescent plasma | Q105209484 | ||
P304 | page(s) | 102922 | |
P577 | publication date | 2020-08-25 | |
P1433 | published in | Transfusion and Apheresis Science | Q15758507 |
P1476 | title | SARS-CoV-2 serology and virology trends in donors and recipients of convalescent plasma |
Search more.